Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

What is the optimal duration of therapy in patients with hepatitis C genotype 2 or 3 infection?: a review.

Acta gastro-enterologica Belgica - 1 Jan 2000

Lasser Luc, Langlet Philippe

Abstract excerpt

Pegylated interferon plus ribavirin is the standard treatment for chronic hepatitis C (HCV). Even if genotype 2 and 3 patients only request a treatment of 24 weeks, this treatment remains very costly and difficult to tolerate due to numerous side effects. Recently several studies focused on the possibility of further reducing treatment duration in chronic HCV genotype 2 and 3 patients without compromising...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genotype
Share to Hepacivirus
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Recombinant Proteins

Share to Ribavirin

Source

Identifiers

PMID: 19198575

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

What is the optimal duration of therapy in patients with hepatitis C genotype 2 or 3 infection?: a review.PMID 19198575Read ↗

Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis.Semantic proximity Read ↗

Effectiveness of extending treatment duration in therapy with pegylated interferon and ribavirin for genotype 2 hepatitis C virus infection.Semantic proximity Read ↗

Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients.Semantic proximity Read ↗

Optimal treatment duration for patients with HCV genotype 1 infection.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 2 patients.Semantic proximity Read ↗

Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review.Semantic proximity Read ↗

Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Optimal therapy in hepatitis C virus genotypes 2 and 3 patients.Semantic proximity Read ↗

Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection.Semantic proximity Read ↗

Chronic hepatitis C therapy: changing the rules of duration.Semantic proximity Read ↗

Expert opinion on the treatment of patients with chronic hepatitis C.Semantic proximity Read ↗

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.